Prognosis
BioNTech to Boost Capacity, Sees Vaccine Beating New Strain
- Companies have projected 1.3 billion doses by end of next year
- BioNTech shot will likely work against U.K. variant, CEO says
This article is for subscribers only.
Pfizer Inc. partner BioNTech SE is pursuing all its options to make more Covid-19 vaccine doses than the 1.3 billion the companies have promised to produce next year, according to the German firm’s chief executive officer.
The companies will probably know by January or February whether and how many additional doses can be produced, Ugur Sahin said late Monday in an interview. “I am confident that we will be able to increase our network capacity, but we don’t have numbers yet.”